Efficacy of Jintiange Capsules in the Treatment of Osteoporosis: A Network Meta‐analysis

Objective To evaluate the efficacy of Jintiange capsules and Jintiange combined with other therapies in the treatment of osteoporosis. Methods A systematic review of the literature was conducted through databases including China National Knowledge Infrastructure (CNKI), the VIP Database for Chinese Technical Periodicals (VIP), Wanfang, and PubMed from inception to April 2018. Network meta‐analysis was used to determine the relative efficacy of related treatments on osteoporosis. The primary outcome measures are the bone mineral density (BMD) of the lumbar and femoral neck, and the secondary outcome measures are visual analog pain score (VAS) and adverse events. Two reviewers independently selected the studies, extracted information, and assessed the quality of included trials. Data extracted from eligible studies was pooled and meta‐analyzed, and the mean differences (MD) with their 95% confidence intervals were estimated as the effect size between treatments. Results Thirty‐one studies were included in this study, containing 28 randomized controlled trials (RCT) and 3 non‐randomized controlled trials (non‐RCT), with a total of 14 regimens treating osteoporosis. According to the surface under the cumulative ranking (SUCRA) curves, Jintiange capsules combined with atorvastatin (89.9%) and Jintiange combined with bisphosphonates (88.2%) have the best efficacy in terms of the BMD of the lumbar and femoral neck, respectively. Based on the VAS, Jintiange combined with calcium has the best analgesic effect (83.4%). Conclusion Jintiange capsules alone and combined with other therapies is a good choice for treating patients with osteoporosis in terms of improving BMD, relieving pain, and reducing adverse events. More large‐scale and well‐designed RCT are warranted to confirm the results of this study.